Bethanechol for Eosinophilic Esophagitis

Overview

The primary goals of this study are to ease the symptoms of patients with Eosinophilic Esophagitis (EoE) and to test the effectiveness of the drug bethanechol in relieving those symptoms.

Full Title of Study: “Bethanechol for Treatment of Eosinophilic Esophagitis (EoE)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2014

Interventions

  • Drug: Bethanechol
    • Due to the fact that this study has only 1 arm and all study subjects will receive the study drug in the same manner and dose, there are no other details to cover.

Arms, Groups and Cohorts

  • Experimental: Bethanechol
    • Oral administration of 25 milligrams of bethanechol taken twice daily for a minimum of 7 days. Total dose taken daily for a minimum of 7 days is 50 mg.

Clinical Trial Outcome Measures

Primary Measures

  • Change From Baseline High Resolution Esophageal Manometry With Impedance to Day 7
    • Time Frame: Day 1 and Day 7
    • The high resolution esophageal manometry with impedance involves a thin, pressure-sensitive tube that is passed through the nose and into the stomach. Once in place, the tube is pulled slowly back into the esophagus (food pipe). When the tube is in the esophagus, the patient is asked to swallow several times while swallowing water, applesauce, crackers, and marshmallows. These swallows will be completed while laying down, sitting upright, and standing. The pressure of the muscle contractions will be measured along several sections of the tube. The tube is removed after the tests are completed. This test allows for a quantitative measure of the pressure in the esophagus that can be correlated to difficulty or ease of bolus swallowing.

Secondary Measures

  • Change From Baseline Evaluation of Esophageal Function Questionnaire to Day 7
    • Time Frame: Day 1 and Day 7
    • This questionnaire allows the patient to assess their own symptoms and report their opinions about drug effectiveness.

Participating in This Clinical Trial

Inclusion Criteria

  • Male or Female – Age 18-75 – Symptoms associated with EoE such as dysphagia, heartburn, vomiting, abdominal pain, food impaction – Subject has signed informed consent for the administration of bethanechol that informs the patient of potential adverse events – Clinically or pathologically proven EoE Exclusion Criteria:
  • Known allergy to bethanechol – Asthma – Pregnant or breast-feeding women – Severe neurological problems – Severe diabetes – Achalasia – Known allergy to lidocaine or other local anesthetic – Hypothyroidism – Peptic ulcer – Pronounced bradycardia or hypotension – Vasomotor instability – Coronary artery disease – Epilepsy – Parkinsonism – Weakened gastrointestinal or bladder wall – Mechanical obstruction of the gastrointestinal tract or bladder neck – Urinary bladder surgery in the 6 months prior to the study – Gastrointestinal resection and anastomosis – Spastic gastrointestinal disturbances – Acute inflammatory lesions of the gastrointestinal tract – Peritonitis – Marked vagotonia
  • Gender Eligibility: All

    Minimum Age: 18 Years

    Maximum Age: 75 Years

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • University of Iowa
    • Provider of Information About this Clinical Study
      • Principal Investigator: Assouline-Dayan, Yehudith, Clinical Assistant Professor – University of Iowa
    • Overall Official(s)
      • Yehudith Assouline-Dayan, MD, Principal Investigator, University of Iowa

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.